Has the recent evidence demonstrating linear growth catch-up and improved bone turnover markers (BALP) with dupilumab changed how you counsel pediatric patients and their guardians?

Has the recent evidence demonstrating linear growth catch-up and improved bone turnover markers (BALP) with dupilumab changed how you counsel pediatric patients and their guardians?

• Yes (Proactively changing counseling to emphasize systemic growth and bone health benefits)
• No (Counseling approach remains focused primarily on skin clearance and baseline risk-benefit)
• Only if patient guardians inquire
• Other